Galena Biopharma, Inc. (GALE) Reaches $0.28 Yearly Low; Shorts at HD Supply Holdings (HDS) Lowered By 10%

December 29, 2017 - By Dolores Ford

HD Supply Holdings Incorporated (NASDAQ:HDS) had a decrease of 10% in short interest. HDS’s SI was 3.07M shares in December as released by FINRA. Its down 10% from 3.41M shares previously. With 1.98 million avg volume, 2 days are for HD Supply Holdings Incorporated (NASDAQ:HDS)’s short sellers to cover HDS’s short positions. The stock increased 0.54% or $0.215 during the last trading session, reaching $40.435. About 663,661 shares traded. HD Supply Holdings, Inc. (NASDAQ:HDS) has risen 25.80% since December 29, 2016 and is uptrending. It has outperformed by 9.10% the S&P500.

The stock of Galena Biopharma, Inc. (NASDAQ:GALE) hit a new 52-week low and has $0.27 target or 3.00% below today’s $0.28 share price. The 5 months bearish chart indicates high risk for the $12.60M company. The 1-year low was reported on Dec, 29 by Barchart.com. If the $0.27 price target is reached, the company will be worth $378,090 less. The stock 0.15% or $0 during the last trading session, reaching $0.276. It is up 98.04% since December 29, 2016 and is downtrending. It has underperformed by 114.74% the S&P500.

Galena Biopharma, Inc., a biopharmaceutical company, develops hematology and oncology therapeutics that address unmet medical needs. The company has market cap of $12.60 million. The firm develops GALE-401 , which completed Phase II clinical trial for the treatment of patients with myeloproliferative neoplasms to lower elevated platelet levels. It currently has negative earnings. It also develops NeuVax (nelipepimut-S), which is in Phase IIb clinical trial in combination with trastuzumab for HER2 1+ and 2+ node positive and high-risk node negative breast cancer patients; Phase II clinical trial in combination with trastuzumab for HER2 3+ breast cancer patients; Phase II clinical trial for women with ductal carcinoma in situ of the breast; and Phase II clinical trial for patients with gastric cancer.

Among 7 analysts covering Galena Biopharma (NASDAQ:GALE), 3 have Buy rating, 0 Sell and 4 Hold. Therefore 43% are positive. Galena Biopharma has $6 highest and $2 lowest target. $4.40’s average target is 1494.20% above currents $0.276 stock price. Galena Biopharma had 17 analyst reports since August 7, 2015 according to SRatingsIntel. FBR Capital downgraded Galena Biopharma, Inc. (NASDAQ:GALE) on Monday, February 6 to “Mkt Perform” rating. The stock of Galena Biopharma, Inc. (NASDAQ:GALE) earned “Outperform” rating by Oppenheimer on Thursday, November 12. The rating was maintained by Maxim Group on Wednesday, August 9 with “Hold”. The company was downgraded on Wednesday, June 29 by Raymond James. MLV maintained the shares of GALE in report on Friday, August 7 with “Buy” rating. As per Friday, March 11, the company rating was maintained by Roth Capital. The firm earned “Outperform” rating on Wednesday, September 9 by Raymond James. The company was maintained on Friday, July 22 by FBR Capital. Cantor Fitzgerald upgraded the stock to “Hold” rating in Tuesday, December 8 report. The firm earned “Buy” rating on Tuesday, November 10 by Roth Capital.

Among 17 analysts covering HD Supply Holdings (NASDAQ:HDS), 7 have Buy rating, 0 Sell and 10 Hold. Therefore 41% are positive. HD Supply Holdings had 48 analyst reports since July 30, 2015 according to SRatingsIntel. Longbow initiated the shares of HDS in report on Thursday, June 2 with “Buy” rating. As per Tuesday, December 5, the company rating was maintained by Robert W. Baird. The stock of HD Supply Holdings, Inc. (NASDAQ:HDS) earned “Overweight” rating by KeyBanc Capital Markets on Friday, December 18. As per Monday, July 10, the company rating was downgraded by Longbow. On Friday, September 8 the stock rating was maintained by Credit Suisse with “Neutral”. The rating was upgraded by JP Morgan on Friday, July 14 to “Overweight”. The rating was maintained by RBC Capital Markets on Wednesday, June 7 with “Buy”. The firm has “Outperform” rating given on Wednesday, December 9 by RBC Capital Markets. The stock of HD Supply Holdings, Inc. (NASDAQ:HDS) has “Sector Perform” rating given on Tuesday, September 20 by RBC Capital Markets. The stock has “Outperform” rating by RBC Capital Markets on Thursday, September 8.

HD Supply Holdings, Inc. operates as an industrial distributor in North America. The company has market cap of $7.51 billion. The companyÂ’s Facilities Maintenance segment offers electrical and lighting items, plumbing, appliances, janitorial supplies, hardware, kitchen and bath cabinets, window coverings, textiles and guest amenities, healthcare maintenance, and water and wastewater treatment products, as well as heating, ventilating, and air conditioning products. It has a 7.77 P/E ratio. The Company’s Waterworks segment provides pipes, fittings, valves, hydrants, and meters for use in the construction, maintenance, and repair of water and waste-water systems, as well as fire-protection systems; and smart meters, fusible piping solutions, and engineered treatment plant services and products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Dolores Ford







Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: